The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy
NCT ID: NCT01041183
Last Updated: 2009-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group I
0.3 mg IV ramosetron
intravenous ramosetron
0.3 mg IV ramosetron (group I)
group II
0.1 mg oral ramosetron
oral ramosetron
0.1 mg oral ramosetron (group II)
group III
0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
oral and IV ramosetron
0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous ramosetron
0.3 mg IV ramosetron (group I)
oral ramosetron
0.1 mg oral ramosetron (group II)
oral and IV ramosetron
0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
25 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seoul National University Bundang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jung-Hee Ryu
Seongnam-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jung-Hee Ryu, Ph.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Ryu JH, Jeon YT, Hwang JW, Oh AY, Moon JY, Ro YJ, Kim CS, Chen C, Apfel CC, Do SH. Intravenous, oral, and the combination of intravenous and oral ramosetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, controlled trial. Clin Ther. 2011 Sep;33(9):1162-72. doi: 10.1016/j.clinthera.2011.07.018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
nasea-LC
Identifier Type: -
Identifier Source: org_study_id